Park Meditech of Lachine, Quebec, the parent company of gammacamera vendor Park Medical, has signed a deal with a Canadiancapital development fund for a private placement worth up to $10million in funds for Park. The fund, Fonds de solidarite des
Park Meditech of Lachine, Quebec, the parent company of gammacamera vendor Park Medical, has signed a deal with a Canadiancapital development fund for a private placement worth up to $10million in funds for Park. The fund, Fonds de solidarite des travailleursdu Quebec (the Fonds), agreed to purchase debentures and commonstock issued by Park.
As part of the deal, Park investors Pinetree Capital and Analogichave agreed to convert debt owed to them by Park into notes andcommon stock. Once the debentures are converted and the deal finalized,the Fonds could own up to 12.5 million shares of Park stock, representing27% of shares outstanding, and would be Park's largest shareholder.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.